UK Markets closed

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.05+2.94 (+7.71%)
At close: 04:00PM EDT
40.72 -0.33 (-0.80%)
After hours: 07:09PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close38.11
Open38.69
Bid41.09 x 900
Ask41.33 x 1000
Day's range38.01 - 41.30
52-week range25.07 - 139.99
Volume2,288,560
Avg. volume1,168,598
Market cap2.037B
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-3.15
Earnings date02 Feb 2022 - 07 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est47.17
  • Motley Fool

    3 Stocks That Could Double by 2025

    Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Investors intent on doubling their money by 2025 might benefit from looking at stocks that seem wildly undervalued and could experience multiple catalysts in the next couple of years. Axsome Therapeutics lagged the market in recent months, primarily because of regulatory roadblocks.

  • Business Wire

    Twist Bioscience to Present at Fujifilm’s 12th Annual Global IT Executive Summit

    SOUTH SAN FRANCISCO, Calif., June 16, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Fujifilm 12th Annual Global IT Executive Summit taking place June 22-25, 2022 at the InterContinental Hotel in San Diego, CA. Mr. Hellmold will present on Thursday, June 2

  • Business Wire

    Twist Bioscience Launches Rapid Turnaround, Customizable Panels to Advance R&D in Minimal Residual Disease (MRD) Detection in Cancer Screening

    SOUTH SAN FRANCISCO, Calif., June 07, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist MRD Rapid 500 Panel1, a custom solution that can be added to a standard next generation sequencing (NGS) workflow, offering fully customizable and highly cost effective panels to detect minimal residual disease (MRD) in as few as five days.